Search
for
Sort by
Research 30 of 1000+
- Prospective cardiovascular evaluation with 24-hour Holter and 24-hour ambulatory blood pressure monitoring in men using 5-mg oral minoxidil for androgenetic alopecia
- From Piezoelectric Nanogenerator to Non-Invasive Medical Sensor: A Review
- Response to “The Role of Patient‐ and Drug‐Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System”
- CARDIOVASCULAR SAFETY OF LOW-DOSE ORAL MINOXIDIL FOR ANDROGENETIC ALOPECIA IN PATIENTS WITH HYPERTENSION OR ARRHYTHMIAS
- Prevalence of Metabolic Syndrome and Cardiovascular Risk Factors in Early Onset Male Androgenetic Alopecia - A Cross Sectional Study in a Tertiary Care Hospital
- Investigation, Treatment, and Monitoring of Late‐Onset Hypogonadism in Males: ISA, ISSAM, and EAU Recommendations
- Gender‐affirming hormone therapy for transgender and gender‐diverse adults in Australia
- The efficacy and safety of oral minoxidil greater than 5 mg daily in hair loss disorders
- Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil
- Gender-Affirming Hormone Therapy for Transgender Men
- Orthostatic symptoms in women treated with low-dose oral minoxidil in the absence of overt hypotension: Implications for clinical practice
- The Association between Metabolic Syndrome Components and Hair Loss both Male and Female Individuals
- Androgen Treatment in Women
- Endocrine Treatment of Transsexual Persons:An Endocrine Society Clinical Practice Guideline
- Endocrine care of transpeople part I. A review of cross-sex hormonal treatments, outcomes and adverse effects in transmen
- Oral minoxidil 7.5 mg for hair loss increases heart rate with no change in blood pressure in 24 h Holter and 24 h ambulatory blood pressure monitoring
- Cardiovascular effects of hormone therapy for prostate cancer
- Association of Primary Cicatricial Alopecia with Subsequent Cardiovascular Disease
- Cardiovascular risk factors and co-morbidities in patients with Alopecia Areata: A case-control study
- Cardiovascular Safety and Benefits of Testosterone Implant Therapy in Postmenopausal Women: Where Are We?
- Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark
- Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome
- The hydroxypropyl‐β‐cyclodextrin‐minoxidil inclusion complex improves the cardiovascular and proliferative adverse effects of minoxidil in male rats: Implications in the treatment of alopecia
- Hormone therapy for transgender patients
- Women’s Health Considerations for Lipid Management
- The Role of the Athletic Trainer in Providing Care to Transgender and Gender-Diverse Patients: Considerations for Medical Affirmation—Part II
- Effects Of Hormone Therapy On The Laboratory Profile Of Transgender People: A Scoping Review
- Alopecia Areata is Associated with Increased Expression of Heart Disease Biomarker Cardiac Troponin I
- Dyslipidemia and obstructive sleep apnea in men with androgenetic alopecia: an analysis from the EPISONO study
- 44179 Characterization of subclinical atherosclerosis in chronic severe alopecia areata.